Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03914495 · ClinicalTrials.gov registry record · NA
The Role of Microbiome Reprogramming on Liver Fat Accumulation
A NA study, sponsored by AdventHealth Translational Research Institute.
- Terminated
- Registry status
- NA
- Development phase
- 57
- Enrollment target
NCT03914495: Clinical Trial NA study, sponsored by AdventHealth Translational Research Institute.
NCT03914495 is a NA study that was terminated before completion, run by AdventHealth Translational Research Institute. The registered enrollment target is 57 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03914495, a NA study, was terminated before completion, sponsored by AdventHealth Translational Research Institute.
- TERMINATED
- Registry status
- NA
- Development phase
- 57 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate whether reprogramming the microbiome via soluble fiber supplementation will decrease liver fat in obese individuals.
Primary Outcome
Liver fat changes will be assessed by MRI-PDFF
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Inulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2019-05-21 |
| Est. Completion | 2021-06-09 |
| Phase | NA |
Why NCT03914495 stopped before completion
NCT03914495 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03914495 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03914495 about?
NCT03914495 is a clinical study titled "The Role of Microbiome Reprogramming on Liver Fat Accumulation". The purpose of this study is to investigate whether reprogramming the microbiome via soluble fiber supplementation will decrease liver fat in obese individuals.
What is the current status of trial NCT03914495?
This trial is currently terminated. It is a NA study. The enrollment target is 57 participants. The study started on 2019-05-21. Estimated completion is 2021-06-09.
What interventions are being tested in trial NCT03914495?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Inulin (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03914495?
This trial is sponsored by AdventHealth Translational Research Institute, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03914495's enrollment target sits among peer trials
57 1261st of 2000 higher than 739 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI